InterventionsHuman trial

CT-388, a cAMP Signal-Biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight/Obesity: A 48-Week Phase 2 Study

ADA Scientific Sessions 2026 Abstract

The paper

LINGVAY I, JASTREBOFF A, LENDER D et al.

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Late-breaking 2813-LB

doi.org/10.2337/db26-2813-lb

Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
The New England Journal of Medicine · 4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026